Melanotan I (MT-I, afamelanotide) and Melanotan II (MT-II) are synthetic analogues of alpha-melanocyte-stimulating hormone (α-MSH). While they're widely known in research circles for their tanning effects, reducing these peptides to "tanning injections" misses the broader picture and the serious side-effect profile that MT-II carries.
What Are Melanotan I and II?
Both peptides were originally developed at the University of Arizona in the 1980s and 1990s. They act on melanocortin receptors (MCRs), a family of five G-protein-coupled receptors involved in pigmentation, inflammation, energy homeostasis, and sexual function.
- Melanotan I (afamelanotide) is a linear peptide analogue of α-MSH. It is a selective MC1R agonist, meaning it primarily targets the receptor responsible for melanin production in the skin.
- Melanotan II is a cyclic peptide with a shorter amino acid sequence. It is a non-selective melanocortin agonist, binding to MC1R, MC3R, MC4R, and MC5R, which explains its wider (and more unpredictable) range of effects.
It's Not Just About Tanning
The melanocortin system is one of the most functionally diverse receptor families in the body. Here's what each receptor subtype is involved in:
| Receptor | Primary Role | MT-I Affinity | MT-II Affinity |
|---|---|---|---|
| MC1R | Skin pigmentation, anti-inflammatory | ✅ High (selective) | ✅ High |
| MC2R | Adrenal steroidogenesis (ACTH receptor) | Minimal | Minimal |
| MC3R | Energy homeostasis, inflammation | Low | ✅ Moderate |
| MC4R | Appetite regulation, sexual function, erectile response | Low | ✅ High |
| MC5R | Sebaceous gland function, immune regulation | Low | ✅ Moderate |
This means MT-II's effects extend well beyond melanogenesis. Research has explored its role in sexual dysfunction (MC4R activation), appetite suppression, and inflammation modulation.
Melanotan I: The Medical Path
MT-I (afamelanotide) has followed a legitimate pharmaceutical pathway. It received EMA approval under the brand name Scenesse® for the treatment of erythropoietic protoporphyria (EPP), a rare genetic condition where sunlight exposure causes severe pain and skin damage. By stimulating eumelanin production via MC1R, it provides a degree of photoprotection.
Research has also explored MT-I for:
- Vitiligo (repigmentation of depigmented patches)
- Polymorphous light eruption (sun allergy)
- Actinic keratosis prevention in organ transplant patients
- General photoprotection in fair-skinned populations
Melanotan II: The Broader (and Riskier) Profile
MT-II has never been approved by any regulatory agency. Its non-selective receptor binding gives it a range of effects that researchers and users report:
- Tanning: MC1R-mediated melanogenesis
- Appetite suppression: MC4R activation in the hypothalamus
- Erectile function / libido: MC4R in the CNS (this pathway led to the development of bremelanotide/Vyleesi®, a derivative of MT-II approved for HSDD)
- Nausea: one of the most common acute side effects
- Facial flushing
- Fatigue and lethargy
The Pigmentation Problem With MT-II
This is one of the most under-discussed risks of MT-II, and one that every researcher should understand before considering this compound.
Uneven and Unwanted Pigmentation
Because MT-II stimulates melanocytes broadly and non-selectively, it doesn't produce an even "natural tan." Users frequently report:
- Darkening of existing moles and nevi: this is well-documented in case reports and is a significant concern because it can mask melanoma progression or mimic atypical moles on dermoscopy.
- New mole formation: several case studies have reported new melanocytic nevi appearing during MT-II use.
- Hyperpigmentation in unexpected areas: including the lips, gums, genitals, areolae, and scars. These areas have higher melanocyte density and respond disproportionately.
- Uneven patchy darkening: rather than a uniform tan, some users develop blotchy or streaky pigmentation, particularly on the face and torso.
The Melanoma Concern
While no causal link has been definitively established, several dermatology case reports have documented:
- Melanoma diagnosed in individuals using MT-II, with concern that the pigment changes masked early warning signs
- Rapid changes in existing moles that prompted biopsies
- Eruptive nevi (sudden appearance of multiple new moles), a recognised risk factor for melanoma
The British Association of Dermatologists and other professional bodies have issued warnings about unlicensed melanotan products, specifically citing the pigmentation risks and inability to monitor moles effectively during use.
Persistence of Pigmentation
Unlike a natural UV-induced tan that fades over weeks, MT-II-induced pigmentation can persist for months after discontinuation. Some users report permanent darkening of moles or freckling that does not resolve. This is thought to be due to irreversible melanocyte activation or proliferation triggered by chronic MCR stimulation.
Head-to-Head Comparison
| Factor | Melanotan I | Melanotan II |
|---|---|---|
| Structure | Linear (13 amino acids) | Cyclic (7 amino acids) |
| Receptor selectivity | MC1R selective | Non-selective (MC1R, MC3R, MC4R, MC5R) |
| Regulatory status | EMA-approved (Scenesse®) for EPP | Not approved anywhere |
| Primary effect | Eumelanin production | Eumelanin + appetite + sexual function |
| Pigmentation quality | More even, gradual | Often uneven, can darken moles |
| Mole/nevi risk | Low (limited data) | Documented: darkening, new nevi, masking melanoma |
| Nausea | Mild to moderate | Common, especially at higher doses |
| Sexual side effects | Minimal | Significant (libido, spontaneous erections) |
| Half-life | ~30 minutes | ~2 to 3 hours |
| Research quality | Clinical trial data available | Mostly case reports and community data |
Key Takeaways for Researchers
- MT-I and MT-II are fundamentally different compounds despite the similar names. MT-I is receptor-selective with a pharmaceutical track record; MT-II is non-selective with no regulatory approval.
- MT-II carries real pigmentation risks, including darkening of moles, new nevi formation, and uneven hyperpigmentation that can persist long after discontinuation.
- The dermatological risks are not theoretical. Published case reports document melanoma concerns, eruptive nevi, and mucosal hyperpigmentation in MT-II users.
- MT-II's effects on appetite and sexual function are well-documented and explain why derivatives like bremelanotide were developed, but the parent compound is far less refined.
- Neither peptide is "just a tanning peptide." The melanocortin system affects inflammation, energy balance, adrenal function, and immune regulation. Any compound targeting this system has systemic implications.
References
- Dorr RT et al. "Effects of supraphysiological doses of MT-II on melanogenesis." Life Sciences, 1996.
- Langan EA et al. "Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'?" British Journal of Dermatology, 2010.
- Hjuler KF, Bhatt DK. "Eruptive melanocytic naevi following melanotan II injection." BMJ Case Reports, 2019.
- MHRA. "Melanotan: unsafe tanning injections." Medicines and Healthcare products Regulatory Agency guidance.
- Habbema L et al. "Efficacy of afamelanotide in erythropoietic protoporphyria." New England Journal of Medicine, 2015 (Scenesse® trial).